Recently, van de Donk et al., using data from the ALCYONE and MAIA trials, developed a predictive model to identify serious infection risks in non-transplant eligible NDMM patients, focusing on factors like age over 75, high lactate dehydrogenase (LDH), low serum albumin, and elevated alanine transaminase (ALT) [16]. The gene discussed is GPT; the disease is infection.